Drug Profile


Alternative Names: K 877; Parmodia

Latest Information Update: 11 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Kowa Pharmaceutical
  • Class Antihyperlipidaemics; Benzoxazoles; Butyric acids; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Hyperlipidaemia
  • Phase III Dyslipidaemias; Hypertriglyceridaemia

Most Recent Events

  • 11 Aug 2017 Chemical structure information added
  • 03 Jul 2017 Registered for Hyperlipidaemia in Japan (PO) - First global approval
  • 16 Mar 2017 Phase-III clinical trials in Dyslipidaemias in Czech Republic, Hungary, Denmark, Bulgaria, Netherlands, Spain and Slovakia (PO) (EudraCT2016-003818-26)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top